<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03080974</url>
  </required_header>
  <id_info>
    <org_study_id>16.1190</org_study_id>
    <nct_id>NCT03080974</nct_id>
  </id_info>
  <brief_title>Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma</brief_title>
  <official_title>Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Louisville</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare the efficacy and tolerability of irreversible electroporation in combination with&#xD;
      Nivolumab in patients with locally advanced pancreatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Immunotherapy and irreversible electroporation in the treatment of advanced pancreatic&#xD;
      adenocarcinoma. This is a Phase II study in which all patients undergoing irreversible&#xD;
      electroporation of locally advanced pancreatic adenocarcinoma will be treated with nivolumab&#xD;
      post-operatively.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 14, 2017</start_date>
  <completion_date type="Anticipated">April 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All patients will undergo irreversible electroporation and treatment with Nivolumab</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of Combination Irreversible Electroporation and Nivolumab Treatment</measure>
    <time_frame>Baseline thru 100 days after receiving last dose</time_frame>
    <description>Adverse events and Serious adverse events will be collected</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Every three months for 4 years.</time_frame>
    <description>CT scans will be reviewed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Every three months for 4 years.</time_frame>
    <description>CT scans will be reviewed</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Pancreatic Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients undergoing irreversible electroporation will be treated with nivolumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Given post-operatively every two weeks for a total of 4 doses. Dose based on weight.</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Irreversible Electroporation</intervention_name>
    <description>Non-thermal ablation of tumor</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  â‰¥ 18 years if age&#xD;
&#xD;
          -  Diagnosed with stage III pancreatic cancer&#xD;
&#xD;
          -  Tumor is measurable&#xD;
&#xD;
          -  Glomerular Filtration Rate &gt; 60 m/L/min/1.73 m(2)&#xD;
&#xD;
          -  Willing and able to comply with the protocol requirements&#xD;
&#xD;
          -  Able to comprehend and have signed the informed consent to participate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participating in another clinical trial for the treatment of cancer at time of&#xD;
             screening&#xD;
&#xD;
          -  Are pregnant or currently breast feeding&#xD;
&#xD;
          -  Have a cardiac pacemaker or Implantable Cardioverter Defibrillator implanted that&#xD;
             cannot be deactivated during the procedure&#xD;
&#xD;
          -  Have non-removable implants with metal parts within 1 cm of the target lesion&#xD;
&#xD;
          -  Had a myocardial infarction within 3 months prior to enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Martin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Louisville</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 14, 2017</study_first_submitted>
  <study_first_submitted_qc>March 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2017</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Louisville</investigator_affiliation>
    <investigator_full_name>Robert C. Martin</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>irreversible electroporation</keyword>
  <keyword>Nivolumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

